

1           Enhanced viral infectivity and reduced interferon  
2           production are associated with high pathogenicity for  
3           influenza viruses

4           Ke Li<sup>\*a</sup>, James M. McCaw<sup>a,b,c</sup>, Pengxing Cao<sup>a</sup>

5           <sup>a</sup>*School of Mathematics and Statistics, The University of Melbourne, Parkville, VIC*  
6            3010, Australia (\* corresponding author: [kl2@student.unimelb.edu.au](mailto:kl2@student.unimelb.edu.au))

7           <sup>b</sup>*Peter Doherty Institute for Infection and Immunity, The Royal Melbourne Hospital and*  
8            *The University of Melbourne, Parkville, VIC 3010, Australia*

9           <sup>c</sup>*Melbourne School of Population and Global Health, The University of Melbourne,*  
10            *Parkville, VIC 3010, Australia*

---

11   **Abstract**

Epidemiological and clinical evidence indicates that humans infected with the 1918 pandemic influenza virus and highly pathogenic avian H5N1 influenza viruses often displayed severe lung pathology. High viral load and extensive infiltration of macrophages are the hallmarks of highly pathogenic (HP) influenza viral infections. However, it remains unclear what biological mechanisms primarily determine the observed difference in the kinetics of viral load and macrophages between HP and low pathogenic (LP) viral infections, and how the mechanistic differences are associated with viral pathogenicity. In this study, we develop a mathematical model of viral dynamics that includes the dynamics of different macrophage populations and interferon. We fit the model to *in vivo* kinetic data of viral load and macrophage level from BALB/c mice infected with an HP or LP strain of H1N1/H5N1 virus using Bayesian inference. Our primary finding is that HP viruses has a higher viral infection rate, a lower interferon production rate and a lower macrophage recruitment rate compared to LP viruses, which are strongly associated with more severe tissue damage (quantified by a higher percentage of epithelial cell loss). We also quantify the relative contribution of macrophages to viral clearance and find that macrophages do not play a dominant role in direct clearance of free virus although their role in mediating immune responses such as interferon production is crucial. Our work provides new insight into the mechanisms that convey the observed difference in viral and macrophage kinetics between HP and LP infections and establishes an improved model fitting framework to enhance the analysis of new data on viral pathogenicity.

## 12 Author Summary

13 Infections with highly pathogenic (HP) influenza virus (e.g., the 1918  
14 pandemic virus) often lead to serious morbidity and mortality. HP influenza  
15 virus infection is characterised by rapid viral growth rate, high viral load  
16 and excessive infiltration of macrophages to the lungs. Despite extensive  
17 study, we do not yet fully understand what biological processes leading to  
18 the observed viral and macrophage dynamics and therefore viral pathogenic-  
19 ity. Experimental studies have previously suggested that bot viral factors  
20 (e.g., viral proteins) and host factors (e.g., the host immune response) play a  
21 role to enhance viral pathogenicity. Here, we utilise *in vivo* kinetic data of vi-  
22 ral load and macrophages and fit a viral dynamic model the data. Our model  
23 allow us to explore the biological mechanisms that contribute to the differ-  
24 ence viral and macrophage dynamics between HP and LP infections. This  
25 study improves our understanding of the role of interferon on distinguishing  
26 immunodynamics between HP and LP infections. Our findings may con-  
27 tribute to the development of next-generation treatment which rely upon an  
28 understanding of the host different immunological response to HP influenza  
29 viruses.

## 30 Introduction

31 Influenza is a contagious respiratory disease caused by influenza virus and  
32 remains a major public concern [1]. Infections associated with the highly  
33 pathogenic (HP) 1918 pandemic H1N1 virus and highly pathogenic avian  
34 H5N1 virus often display severe lung pathology, causing fatal infection out-  
35 comes in humans [2, 3, 4]. Animal models have been used to understand the  
36 mechanisms of viral pathogenicity [5, 6, 7, 8]. High pathogenicity of viruses  
37 is often determined by pathogenic outcomes (e.g., the clinical outcomes of  
38 infection) in humans [2, 3, 9, 10]. The pathogenicity of influenza virus is  
39 not only associated with viral factors (e.g., viral HA protein), but is also  
40 influenced by host factors (e.g., the strength of inflammatory response), as  
41 reviewed in [11]. For example, although macrophages are important to or-  
42 chestrate the host immune response, they are also implicated to damage cells  
43 through secreted inflammatory cytokines [12, 13, 14, 15]. Some HP viruses  
44 can use macrophages as target cells and produce new virus from infected  
45 macrophages, altering the antiviral role of macrophages and contributing to  
46 viral infection [12, 16, 17]. Perrone et al. compared the outcome of infections  
47 with HP and LP strains of two influenza A viruses (i.e., the 1918 pandemic  
48 H1N1 virus and an H5N1 virus) in mice and showed that high-pathogenic  
49 viruses exhibited a significant higher viral load as early as one day post-  
50 infection and a higher number of macrophages in the lungs [18]. However,

51 the temporal dynamics of these viral or host factors, and so the major deter-  
52 minants of the observed differences in viral and macrophage kinetics between  
53 HP and LP, remain poorly understood.

54 Mathematical models have been used to study infection dynamics of in-  
55 fluenza virus and its interactions with the host immune response (reviewed  
56 in [19]). To explore the potential mechanism(s) leading to the observed dif-  
57 ference in viral loads and macrophages between HP and LP infections in the  
58 study by Perrone et al. [18], Pawelek et al. fitted a mathematical model to  
59 the viral load and macrophage data and found that a higher activation rate  
60 of macrophages and an active production of virus by macrophages infected  
61 by HP viruses are key drivers leading to higher viral loads and more excessive  
62 number of macrophages [20]. More recently, Ackerman et al. [21] fitted a set  
63 of mathematical models with different hypothesised mechanisms—leading  
64 to distinct immunoregulatory behaviours (e.g., macrophage dynamics)—to  
65 strain specific immunological data from [22]. They identified that different  
66 interferon production rates are the main causes of variance between infec-  
67 tion outcomes in mice infected with low-pathogenic H1N1 or high-pathogenic  
68 H5N1 influenza viruses. The two modelling studies provided useful insights  
69 into the mechanisms of high pathogenicity and set a framework for assessing  
70 other potential mechanisms.

71 The two modelling studies [20, 21] also left aspects for improvement, both  
72 biologically and methodologically. Interferon-mediated immune response,  
73 which has been shown to be important for reducing epithelial loss [23], was  
74 not considered in [20]. Although the study by Ackerman et al. modelled in-  
75 terferon, they did not compare HP and LP viruses of the same type (rather  
76 they compared H5N1 HP vs. H1N1 LP) [21]. Through this study, we aim to  
77 identify viral and host factors that determine the observed difference in viral  
78 load and macrophage kinetics between HP and LP viruses from same pheno-  
79 type. Besides, both modelling studies used least-squares method to provide  
80 point estimates to model parameters, which may not accurately quantify the  
81 uncertainty of estimated parameters and therefore limits our ability to draw  
82 reliable conclusions based on parameter estimates [24]. Recent advances in  
83 Bayesian statistical inference provides an improved framework for param-  
84 eter estimation and quantification of uncertainty [25] and can be applied  
85 to modelling viral dynamics. We would like to address the above limita-  
86 tions by building an improved framework to study the mechanisms for viral  
87 pathogenicity.

88 In this study, we develop a novel mathematical model which includes  
89 macrophage dynamics (i.e., resting,  $M_1$  and  $M_2$  macrophages), interferon-

90 mediated immune response and essential interactions between macrophage  
91 and virus. Under a Bayesian statistical framework, we fit the model to  
92 available *in vivo* kinetic data for both virus and macrophage populations of  
93 both highly pathogenic and paired low pathogenic strains of H1N1 or H5N1  
94 viruses. We use the data-calibrated model to generate and compare a set  
95 of metrics that have been used as surrogates for viral pathogenicity [26, 27].  
96 We identify the important role of interferon on distinguishing immunody-  
97 namics and the antiviral role of macrophages between HP and LP infections.  
98 We also demonstrate that our model reliably captures observed pathogenic  
99 behaviours (e.g., the severity of epithelium loss) and provides quantitative  
100 estimation of the proportion of damaged cells during HP and LP infections.

## 101 Results

### 102 *Severe tissue damage in HP infection*

103 We fit our model to both viral load and macrophage data of HP and LP  
104 strains simultaneously under a Bayesian framework (the details of model and  
105 statistical implementation, and full diagnostics on the statistical procedures  
106 are provided in the Materials and Methods). Model fitting results for H1N1  
107 virus are given in Fig 1. Our model successfully captures the trends of  
108 both viral load (Fig 1A) and macrophage number (Fig 1B) for both the  
109 HP and LP strains of H1N1 virus and a low level of overlapping of the  
110 95% prediction interval (PI, shaded area) between HP and LP suggests that  
111 the quantitative differences in viral load and macrophage are primarily due  
112 to different parameter values associated with different strains rather than  
113 measurement error. Similar fitting results are observed for infection with the  
114 HP and LP strains of H5N1 virus (Figs 1C and 1D).

115 Using the calibrated model, we then calculate the maximal fraction of  
116 epithelium loss (defined by Eq. 14 in Materials and Methods) and the cumu-  
117 lative dead cells (Eq. 15 in Materials and Methods) during infection which are  
118 difficult to measure experimentally but are important indicators of infection  
119 severity. For H1N1 virus, our model predicts a much larger proportion of ep-  
120 ithelial cells (median value 18.4%, 95% predict interval (PI): [3.4%, 97.4%])  
121 are damaged during the HP infection compared to that in the LP infection  
122 (median value 0.06%, 95% PI: [0.01%, 0.6%]), as shown in Fig 2A. Similarly  
123 for the cumulative number of dead cells shown in Fig 2B, We observe that  
124 there is a high cumulation of dead cells (median  $\log_{10}(AUC_D)$  8.5, 95% PI:  
125 [7.7, 8.9]) in the HP infection whereas the cumulation of dead cells is low in  
126 LP infection (median  $\log_{10}(AUC_D)$  6.2, 95% PI: [5.5, 7.1]).




Figure 1: **Results of model fitting for virological and macrophage data.** Data are presented by solid circles for HP and solid triangles for LP strains. As mentioned in the Materials and Methods, the data were adopted from [18]. We performed 6000 model simulations based on 6000 posterior samples from the posterior distributions of estimated parameters (see SFigs 1 and 2 in *Supporting Information*). (A, B) show a 95% prediction interval (shaded area) of viral load and macrophage for HP (red) and LP (green) strains of the H1N1 viruses, respectively. Solid lines are illustrative viral and macrophage trajectories that are computed based on the basic reproduction number from posterior samples (see Eq. 13 Materials and Methods). (C, D) show the data and model predictions of viral load and macrophage dynamics for HP and LP strains of the H5N1 viruses, respectively.

127 *A high viral infectivity and a low interferon production contribute to severe*  
128 *tissue damage in HP infection*

129 Given the significant difference in tissue damage between HP and LP  
130 virus, we now investigate the underlying biological processes responsible for  
131 the differences. We examine the six biological model parameters that may  
132 convey the difference between HP and LP virus (i.e., the six parameters  
133 assumed to be different between HP and LP in model fitting). To make a  
134 direct comparison, we present the ratio of HP's estimate to LP's estimate for  
135 each parameter in Fig 3 (note that for each parameter there are 6000 ratio  
136 values calculated by 6000 paired HP and LP posterior values and thus we




Figure 2: **Prediction of tissue damage for H1N1 viruses.** The violin plots (coloured) and boxplots (white) give the density and the median and extrema of predicted quantity. (A) model prediction of the maximal epithelium loss for the HP (yellow) and LP (green) strains. (B) model prediction of the cumulative level of dead cells during the infection for both strains.  $***p < 0.001$ . Calculation formula see Eqs. 14 and 15 in the Materials and Methods. All estimations are computed using 6000 posterior samples from model fitting. The estimations for the H5N1 viruses are given in SFig3 in *Supporting Information*

137 show the distribution of the 6000 ratio values in the figure). We observe that  
138 for H1N1 the HP strain has a significantly higher viral infectivity  $\beta$  (99.7% of  
139 the ratio samples are greater than 1 as indicated by dark green. Figs 3B and  
140 3C compare the interferon production rate from infected cells,  $q_{FI}$ , and from  
141 activated macrophages,  $q_{FM}$ , respectively. We find that although the HP  
142 strain has a decreased  $q_{FI}$ , such that 98.9% ratio samples are lower than 1  
143 (indicated by light green), there is no strong evidence to indicate a difference  
144 in  $q_{FM}$ , i.e., approximately half of the posterior estimates for ratios are above  
145 1 (47%) and half below 1 (53%). The results demonstrate that the HP virus  
146 is more capable of infecting susceptible cells and reducing interferon response  
147 from infected cells. The results are supported by a variety of experimental  
148 studies where enhanced infection and replication rates [28, 29] and attenuated  
149 interferon production rates [9, 12, 13, 30, 31, 32, 33, 34, 35] are evidenced as  
150 possible explanations to high viral pathogenic.

151 Fig 3D shows that the rate of infection-induced macrophage recruitment  
152  $s_V$  is lower for the HP strain (98.4% of the ratio samples are less than 1),  
153 suggesting that a high recruitment rate is not the cause for the observed  
154 high level of macrophages during the HP infection seen in Fig 2. Instead,  
155 our model result indicates that high level of macrophages is due to a higher  
156 number of infected cells which activate more macrophages. A similar finding  
157 was shown by Shoemaker et al. who found that a strong inflammation-




Figure 3: **Comparison of estimated model parameters between HP and LP strains of the H1N1 viruses.** Histograms show the frequency of the ratios of estimated HP parameters over paired LP model parameters and are normalised to  $[0,1]$ . The ratios are presented by distributions of 6000 samples because they are generated by 6000 posterior parameter values. The cumulative density functions (CDFs) are given by the solid lines, and the dashed lines indicate ratios = 0. All ratios are  $\log_{10}$ -scaled, such that ratios  $> 0$  (dark green) suggest greater values of the HP parameters. Figs (A, B, C) show the ratios of viral infectivity, interferon production rate from infected cells and activated macrophages, respectively. Figs (D, E, F) show the ratios of infection-induced macrophage recruitment rate, macrophage-mediated virus clearance rate and antibody neutralisation rate, respectively. The model parameter comparison for the H5N1 viruses is given in SFig 5 in *Supporting Information*.

158 associated gene expression occurs once a threshold virus titer is exceeded,  
 159 demonstrating a strong dependency between the extent of inflammation and  
 160 the level of virus titer [22].

161 We further examine how the difference of estimated parameters between  
 162 HP and LP is associated with the different estimated level of tissue dam-  
 163 age shown in Fig 2. We calculate the Partial Rank Correlation Coefficients  
 164 (PRCCs) between the ratio of estimated parameters and the ratio of epithe-  
 165 lium loss between HP and LP strain. We find that the interferon production

166 rate  $q_{FI}$  and infection-induced macrophage recruitment rate  $s_V$  are the two  
167 leading factors determining the maximum epithelium loss (Fig 4A) and they  
168 are negatively correlated with the maximum epithelium loss (PRCC =  $-0.87$   
169 and  $-0.85$  respectively). Analysing the cumulative number of dead cells us-  
170 ing the same method, We also find that  $q_{FI}$  and  $s_V$  are the two leading  
171 parameters driving the difference in the cumulative number of dead cells  
172 (Fig 4B), with again negative correlations (PRCC =  $-0.61$  and  $-0.86$ ). By  
173 contrast, the ratio of viral infectivity  $\beta$  has a relatively small effect on the  
174 ratio of maximum epithelium loss and on the ratio of cumulative number  
175 of dead cells. Our results suggest a critical role of interferon in protect-  
176 ing epithelium loss and tissue damage, given  $q_{FI}$  directly determines the  
177 rate of interferon production and  $s_V$  has an indirect contribution via gener-  
178 ating more  $M_1$  macrophages that directly promotes the rate of interferon  
179 production (see model equation Eq. 8 in the Materials and Methods). The  
180 results are consistent with the earlier finding that interferon can retain a  
181 large healthy epithelial cell pool for viral re-infections [23] and supported by  
182 Ackerman et al. [21] who found that different interferon production rates  
183 are the main causes of variance between infection outcomes in mice infected  
184 with low-pathogenic H1N1 or high-pathogenic H5N1 influenza viruses.

### 185 *The role of macrophages on viral clearance*

186 As described in the introduction, the reduced antiviral effect of macrophages  
187 may contribute to viral pathogenicity. We here analyse the role of macrophages  
188 on viral clearance in both HP and LP infections. In our model, viruses are  
189 cleared through three ways: natural decay, macrophage phagocytosis and  
190 antibody neutralisation. We use the equation (Eq. 16 in the Materials and  
191 Methods) to quantify the contribution of macrophage phagocytosis over the  
192 period of infection by a fractional value (e.g., 0 means no contribution and 0.5  
193 means 50% of viral clearance rate is due to macrophage phagocytosis). The  
194 prediction interval (PI) can be used to quantify the uncertainty of the contri-  
195 bution fraction. As shown in Fig 5, for H1N1 virus, 95% of model predicted  
196 fractions of the contribution of macrophages to viral clearance (indicated by  
197 the 90% PI) are below 20% for HP and are below 45% for LP. The upper  
198 bounds of the contribution fractions drop significantly for high-confidence  
199 range of model predictions, e.g., 60% of of model predicted fractions (indi-  
200 cated by the 20% PI) are less than 0.5% for HP and less than 1.1% for LP.  
201 The results indicate the antiviral effects of macrophages is limited in both  
202 LP and HP infections, and the relative contribution is even smaller in HP in-  
203 fection. We also compare the relative contribution of macrophages in the HP






Figure 4: **Correlations between estimated model parameters and tissue damage.** Partial rank correlation coefficients (PRCC) are calculated with respect to (A) the ratio of max epithelium loss between HP and LP strains, and (B) the ratio of the cumulative dead cells between HP and LP strains of H1N1 viruses. Between the two red dashed lines represents the statistically insignificant values of PRCC. Calculations are based upon 6000 posterior samples from model fitting.

204 and LP H5N1 viruses and find a similar result as in the H1N1 viruses (SFig 6  
 205 in *Supporting Information*). The result suggests that although macrophages  
 206 are critical to orchestrate the host immune responses, i.e., initiate and resolve  
 207 pulmonary inflammation, they are unlikely to be the dominant mechanism  
 208 to clear free virus.

#### 209 *Predicting the effective ways to reduce tissue damage*

210 We have identified three parameters,  $\beta$ ,  $q_{FI}$  and  $s_V$ , that primarily deter-  
 211 mine the difference in tissue damage (quantified by the maximum fraction of  
 212 epithelium loss and the cumulative death cell number). This provides insight  
 213 into the potential targets for the treatment of HP viral infection. Figs 6A, B  
 214 and C show the impact of varying  $\beta$ ,  $q_{FI}$  and  $s_V$  on the maximal fraction of  
 215 epithelium loss, respectively. We find that decreasing  $\beta$  prevents epithelium  
 216 loss in both HP and LP infections (Fig 6A). We also observe that increasing  
 217 interferon production rate  $q_{FI}$  reduces the epithelium loss for the two strains,  
 218 but the effect is nonlinear (Fig 6B). For example, doubling the production




Figure 5: **The relative contribution of macrophages on viral clearance in the HP and LP strains of the H1N1 viruses.** The prediction interval (PI) is calculated based upon the 6000 posterior samples from model fitting. The median trajectory is indicated by black curve (on the bottom). The predictions for the H5N1 viruses are given in SFig 7 in *Supporting Information*.

219 rate halves the epithelium loss, (i.e., epithelium loss is reduced from 30% to  
 220 15% for HP and from 0.12% to 0.06% for LP). Reducing 90% of cell loss,  
 221 however, requires a 10-time increase of  $q_{FI}$ . Furthermore, Fig 6C shows that  
 222 an enhanced infection-reduced macrophage recruitment rate  $s_V$  has almost  
 223 no influence on epithelium loss for the HP virus. In contrast, it reduces  
 224 epithelium loss for the LP virus. Note that although the actual magnitude  
 225 change of epithelium loss is minor for the LP strain, the percentage change is  
 226 comparable between the two strains. Figs 6D, E and F show the dependency  
 227 of cumulative death cell number upon  $\beta$ ,  $q_{FI}$  and  $s_V$ , respectively. We find  
 228 the cumulative death cell number is sensitive to all three parameters for both  
 229 HP and LP strains. The results imply that the maximal epithelium loss and  
 230 the cumulative level of dead cells are strongly associated with  $\beta$  and  $q_{FI}$ ,  
 231 and reducing viral infectivity or boosting interferon production can prevent  
 232 epithelium loss. The results also suggest enhancing macrophage recruitment  
 233 rate  $s_V$  during infection can reduce the dead cell accumulation.




Figure 6: **Parameter driving tissue damage for the H1N1 viruses.** Solid lines are for the HP and dashed lines are for the LP strains. Figs (A, B, C) give the sensitivity analyses of the impact of  $\beta$ ,  $q_{FI}$  and  $s_V$  on maximal epithelium loss. Figs (D, E, F) show the impact of the same three model parameters on the cumulative dead cells.

## 234 Discussion

235 In this work, we identified biological mechanisms that are associated with  
 236 high pathogenicity of *in vivo* H1N1 and H5N1 infections through fitting a  
 237 viral dynamic model to experimental data under a Bayesian framework. Our  
 238 findings support and contribute to the current knowledge that is relevant  
 239 to two frequently studied experimental explanations on the drivers of high  
 240 pathogenicity for influenza viruses (i.e., a higher viral infectivity and a re-  
 241 duced interferon response). Estimated marginal posterior densities of model  
 242 parameters demonstrate that HP viruses have enhanced viral infection rates  
 243 (i.e., higher  $\beta$ ) and reduced interferon production rates (i.e., lower  $q_{FI}$ ) com-  
 244 pared to LP viruses. Our estimation results also explain the difference in  
 245 viral and macrophage kinetics between HP and LP infections. As shown by  
 246 previous studies [23, 36, 37], a higher viral infection rate leads to a faster  
 247 viral growth and an attenuated interferon production leads to a higher peak  
 248 viral loads.

249 Our work quantified the difference of tissue damage between HP and LP  
 250 infections. We predicted a larger proportion of epithelium loss and a high  
 251 level of dead cells are caused in HP infections (Fig 2 for H1N1 and SFig 3 for  
 252 H5N1 in *Supporting Information*). Our model predictions—a high fraction  
 253 of epithelium loss and a high level of dead cells in HP infection—are sup-  
 254 ported by clinical evidence. Severe destruction of lung tissue [2] and severe

255 tissue consolidation with unique destruction of the lung architecture [2, 38]  
256 have been seen in patients infected with HP influenza viruses, leading to lung  
257 pathology [28, 39, 40, 30, 41]. The severity of tissue damage also resulted  
258 in different mechanisms of viral resolution. While target cell depletion re-  
259 mains a mechanism to limit viral replication in HP infections, a timely and  
260 strong activation of immune response explains viral resolution in LP infec-  
261 tions (SFig 4 in *Supporting Information*). As shown by Cao and McCaw, the  
262 mechanisms for viral control can strongly influence the predicted outcomes  
263 of antiviral treatments [42]. For example, different viral dynamics (e.g., long-  
264 last infection or chronic infection) were observed in response to an increasing  
265 drug efficacy when target cell depletion is a mechanism for viral resolution.  
266 In contrast, a consistent viral behaviour (i.e., an early clearance and a shorter  
267 infection) was observed when drug efficacy increased in an immune response  
268 driven viral resolution model. Therefore, the analysis of the influence of an-  
269 tiviral treatment on HP and LP infections is a promising future direction  
270 based on our work.

271 Using a Bayesian statistical method, our modelling work demonstrated  
272 that high virulence of H1N1 and H5N1 viruses, and our estimation pro-  
273 vided evidence to previous experimental work. Although our work identified  
274 HP and LP viruses differ in viral infectivity and interferon production rate,  
275 we cannot (and do not attempt to) rule out other possible mechanisms or  
276 drivers of high pathogenicity proposed in literature. For example, production  
277 of virus by infected macrophages could be an important factor influencing  
278 viral pathogenicity [17], although there is conflicting evidence on whether  
279 macrophages can be productively infected by influenza virus [15, 16, 43].  
280 The abortive or productive infection of macrophages may also be strain-  
281 dependent and/or macrophage-dependent (i.e., resident or monocyte-derived  
282 macrophages) [17]. Thus, we have not explicitly investigate this mechanism  
283 in our study.

284 Viral dynamical models are particularly useful in the quantification of  
285 modelled biological processes by fitting to experimental data [19]. In this  
286 work, we fit our model to both viral load and macrophage data to estimate  
287 model parameters. Although consistent with earlier studies where both viral  
288 load and macrophages were used in model fitting, the effect of incorporating  
289 macrophage data into model fitting remains unclear. Using a simulation-  
290 estimation method, we showed that macrophage data provides valuable infor-  
291 mation on parameter estimation, reducing the uncertainty of predicted time  
292 series of macrophages and estimates of the recruitment rates of macrophages  
293 (i.e.,  $s_M$  and  $s_V$ ). By contrast, viral load data alone are insufficient to reli-

ably recover macrophage dynamics (see S3 Text in *Supporting Information*).  
Macrophages have been shown to clear viruses by internalisation and lysosomal degradation [44, 45], but their relative contribution to viral clearance compared to other pathways has not been quantified. Our model predicted the contribution of macrophages on viral clearance (among all the modelled mechanisms for viral clearance) is relatively small in both HP and LP infections of H1N1 (Fig 5) and H5N1 (SFig 6 in *Supporting Information*) viruses, suggesting that macrophages may not play a dominant role in direct clearance of free virions. Our model also suggests that the relative contribution of macrophage to viral clearance in HP viral infection is smaller than that in LP infection. This is because resident macrophages ( $M_R$ ) do not replenish during HP infection while they can quickly replenish in LP infection (SFig 7 in *Supporting Information*), which increases the available macrophages to participate in viral clearance. Another mechanism [15] related to productive replication of HP viruses in macrophages has been to have significant consequences for the antiviral functions of macrophages, as reviewed in [17].

Our study has some limitations. Rather than explicitly modelling the dynamics of CD8<sup>+</sup> T cells and antibodies [36, 46], we used hill functions to capture their dynamics. We assumed the adaptive immune response dominates infected cell or viral clearance at day 5 post infection regardless of macrophage dynamics. Macrophages, however, have been shown to act as antigen presenting cells and mediate the activation of different arms of adaptive immunity. For example,  $M_1$  type macrophages help to activate the cellular adaptive immune response whereas  $M_2$  type macrophages contribute to the activation of humoral adaptive immunity [47, 48]. Extension of the model to include the interactions between different populations of macrophages and adaptive immunity is important but requires additional data on the adaptive immune response for both HP and LP, which are not immediately available in the literature. Another limitation is that we did not estimate conversion rates between different populations of macrophages, such as  $k_1$  and  $k_2$ , due to a lack of detailed macrophage kinetic data. As a result, the kinetics for each specific macrophage population could not be calibrated against data. The interactions among macrophage populations, e.g., the rate of conversion from one type to another, could be an important factor to understand influenza disease severity. In future work, our model can be used to estimate the relevant parameters and predict detailed macrophage dynamics given availability of data of different macrophage populations.

332 **Materials and Methods**

333 *Mathematical Models*

334 In this study, we incorporated a dynamic model of macrophages into a  
 335 viral dynamic model. The model explicitly considered the conversion among  
 336 different populations of macrophages, essential interactions between virus  
 337 and macrophages, and different arms of immune responses. The model is  
 338 described by a set of ordinary differential equations (ODEs).




Figure 7: **A model diagram of immune response to influenza viral infection.** Detailed model (Eqs. 1–10) description is given in Materials and Methods. Plus (+) superscript indicates the promotion of a biological process, and minus (–) superscript means the inhibition of a process. In brief, influenza virus ( $V$ ) turns susceptible epithelium cells ( $T$ ) into eclipse-phase infected cells ( $L$ ) which in turns, become infected cells ( $I$ ) that actively produce new virus. Virus also infects resting macrophages ( $M_R$ ) and turns them into pro-inflammatory macrophages ( $M_1$ ). Virus is cleared through the  $M_R$  macrophage ingestion and antibody neutralisation. Infected cells ( $I$ ) and  $M_1$  macrophages produce interferons ( $F$ ) that turns susceptible cells ( $T$ ) into refractory cells ( $R$ ). The refractory cells ( $R$ ) lose protection and turn back to  $T$ . Infected cells ( $I$ ) are killed and become dead cells ( $D$ ) through interferons- and  $CD8^+$  T cells-mediated clearance.  $M_1$  macrophages clear dead, which facilitates the conversion of  $M_R$  to anti-inflammatory  $M_2$  macrophages. Both activated  $M_1$  and  $M_2$  macrophages convert back to  $M_R$  macrophages at certain rates. For clarity, flows depicting the natural decay of activated macrophages ( $M_1$  and  $M_2$ ), virus ( $V$ ) and interferons ( $F$ ), and the replenishment of resting macrophages ( $M_R$ ) and target cells ( $T$ ) are not showed in the diagram.

339 Eqs. 1–3 describe the detailed macrophage dynamics. In the absence of  
 340 viral infection, we assume all macrophages are resting macrophages ( $M_R$ ),

341 and  $M_R$  is assumed to have a constant supplementary rate and decay rate  
342 at  $s_M$  and  $\delta_{MR}$  per day, respectively. Thus, the number of macrophages is  
343 stable at homeostasis, such as  $M_R^* = s_M/\delta_{MR}$  in a disease-free condition. In  
344 the presence of viral infection, influenza virus acting as a perturbation to  
345 macrophage dynamics, activates  $M_R$  macrophages, turning them into pro-  
346 inflammatory macrophages  $M_1$  at a maximal rate  $k_1$ . The activation is in-  
347 fluenced by viral load ( $V/(V + V_{50})$ ) and regulated by anti-inflammatory  $M_2$   
348 macrophages ( $1/(1 + \alpha M_2)$ ). Activated  $M_1$  macrophages convert back to  
349 the resting macrophages or decay at constant rate  $k_{-1}$  and  $\delta_{MA}$  per day, re-  
350 spectively. The  $M_2$  macrophages regulate the activation of  $M_1$  macrophages  
351 to avoid excessive inflammatory response [49].  $M_1$  macrophages phagocyte  
352 apoptotic and dead cells, producing regulatory cytokines (not explicitly mod-  
353 elled), which is represented by  $M_1 D/(D + D_{50})$ . In the presence of these  
354 cytokines, resting macrophages  $M_R$  convert to  $M_2$  macrophages at a maxi-  
355 mal rate  $k_2$ . Activated  $M_2$  macrophages decay or convert back to the resting  
356 state at constant rates  $\delta_{MA}$  and  $k_{-2}$ , respectively.

357 Eqs. 4–7 describe the interaction between virus and epithelial cells, and  
358 between virus and the host immune responses. In detail, epithelial cells ( $T$ )  
359 are infected by influenza virus ( $V$ ) and become latent-state infected cells ( $L$ )  
360 which do not produce new viruses at an infectivity rate  $\beta V$  per day. The  
361 susceptible epithelial cells are protected and convert to refractory cells ( $R$ )  
362 in the presence of interferon ( $F$ ) at a rate  $\phi F$  per day, and refractory cells  
363 convert back to susceptible cells at a rate  $\xi_R$ . We also assume susceptible  
364 cells are replenished at a rate  $g_T(T + R)(1 - (T + I + R)/T_0)$ , where  $T_0$   
365 is the maximal number of epithelial cells that line the upper respiratory  
366 tract. Infected cells in eclipse phase convert to infected cells ( $I$ ) that actively  
367 produce virus at a rate  $\ell$  per day. Three mechanisms are considered for the  
368 clearance of infected cells ( $I$ ), such as natural decay at a constant rate  $\delta_I$   
369 per day; interferon-mediated clearance at a rate  $\kappa_F F$  per day, and CD8<sup>+</sup> T  
370 cells mediated infected clearance at a rate  $\kappa_E t^4/(t^4 + t_E^4)$  per day. Note that  
371 we do not explicitly model the dynamics of CD8<sup>+</sup> T cells. A hill function  
372 is used to represent the activation of adaptive immunity, we set  $t_E$  as 5 so  
373 that CD8<sup>+</sup> T cells only play a significant role after day 5 post infection as  
374 showed in [50]. New virus is produced by  $I$  at a rate  $p_I I$  viruses per day.  
375 The decrease of virus is either due to natural decay, macrophage-mediated  
376 phagocytosis or antibody neutralisation at a rate  $\delta_V, q' M_R, \kappa_A t^4/(t^4 + t_A^4)$   
377 per day, respectively.

378 Eqs. 8–9 describe the one of the interferon dynamics and the dynamics  
379 of refractory cells. We assume Interferon ( $F$ ) is produced either by infected

380 cells ( $I$ ) or macrophages ( $M_1$ ) at a rate  $q_{FI}I$  or  $q_{FM}M_1$  unit of interferons  
 381 per day, respectively, and decay rate a rate  $\delta_F$  per day. The dynamics of  
 382 dead cells ( $D$ ) is described by Eq. 10. Cleared infected cells ( $I$ ) become dead  
 383 cells ( $D$ ) through  $\delta_I I$ ,  $\kappa_F F I$  and  $\kappa_E t^4 / (t^4 + t_E^4)$ , and dead cells is removed  
 384 from the system either due to natural decay at a rate  $\delta_D$  per day or killed by  
 385 macrophages  $\kappa_D M_1$  per day.

$$\frac{dM_R}{dt} = s_M - \delta_{MR}M_R - k_1(V, M_2)M_R + k_{-1}M_1 - k_2(D, M_1)M_R + k_{-2}M_2, \quad (1)$$

$$\frac{dM_1}{dt} = s_V I + k_1(V, M_2)M_R - k_{-1}M_1 - \delta_{MA}M_1, \quad (2)$$

$$\frac{dM_2}{dt} = k_2(D, M_1)M_R - k_{-2}M_2 - \delta_{MA}M_2, \quad (3)$$

$$\frac{dT}{dt} = g_T(T + R) \left( 1 - \frac{T + I + R}{T_0} \right) - \beta TV - \phi FT + \xi_R R, \quad (4)$$

$$\frac{dL}{dt} = \beta TV - \ell L, \quad (5)$$

$$\frac{dI}{dt} = \ell L - \delta_I I - \kappa_F F I - \kappa_E \frac{t^4}{t^4 + t_E^4} I, \quad (6)$$

$$\frac{dV}{dt} = p_I I - \delta_V V - q' M_R V - \kappa_A \frac{t^4}{t^4 + t_A^4} V, \quad (7)$$

$$\frac{dF}{dt} = q_{FI} I + q_{FM} M_1 - \delta_F F, \quad (8)$$

$$\frac{dR}{dt} = \phi FT - \xi_R R, \quad (9)$$

$$\frac{dD}{dt} = \delta_I I + \kappa_F F I + \kappa_E \frac{t^4}{t^4 + t_E^4} I - \kappa_D M_1 D - \delta_D D, \quad (10)$$

386 where  $k_1(V, M_2) = k_1 \frac{V}{V+V_{50}} \frac{1}{1+\alpha M_2}$  and  $k_2(D, M_1) = k_2 \frac{D}{D+D_{50}} M_1$ .

### 387 *Statistical Inference*

388 *In vivo* kinetic data of both virus and macrophage population were ex-  
 389 tracted using WebPlotDigitizer (version 4.4) from [18]. Female BALB/c mice  
 390 were intranasally infected with HP (A/1918 H1N1 and A/Thailand/16/2004  
 391 H5N1) and LP (A/Texas/36/91 and A/Thailand/SP/83/2004) influenza viruses,  
 392 and lungs were harvested for viral load and macrophage measurement at var-  
 393 ious time points post infection. Three mice were measured per time point  
 394 for infection with each viral strain.



395 We applied a Bayesian inference method to fit the dynamic model (de-  
396 tailed in **Mathematical Models**) to the log-transformed virological and  
397 macrophage data. In detail, we use the model to estimate 8 parameters, and  
398 the parameter space is denoted as  $\Phi = (s_V, \beta, q_{FI}, q_{FM}, s_M, \kappa_A, q', V_0)$ . Upon  
399 model calibration, we fixed all other parameters to previous estimated values  
400 in the literature. We fixed the parameter values because the experimental  
401 study [18] does not provide sufficient data for parameter estimation. The  
402 fixed parameter values are given in S2 Text in *Supporting Information*.

403 We assumed HP and LP viruses differ in  $s_V, \beta, q_{FI}, q_{FM}, \kappa_A, q'$  but have  
404 same  $s_M$  and  $V_0$ . This is a reasonable assumption given inbred mice hav-  
405 ing similar number macrophages in the absence of infection (i.e., same  $s_M$ ),  
406 and inoculation size is same for HP and LP infection (i.e., same  $V_0$ ). The  
407 prior distribution for the estimated model parameters is given in S2 Text in  
408 *Supporting Information*. The distribution of the observed log-transformed  
409 viral load and macrophage data is assumed to be a normal distribution with  
410 a mean value given by the model simulation results and standard deviation  
411 (SD) parameter with prior distribution of a normal distribution with a mean  
412 of 0 and a SD of 1.

413 Model fitting was performed in R (version 4.0.2) and Stan (Rstan 2.21.0).  
414 Samples were drawn from the joint posterior distribution of the model param-  
415 eters using Hamiltonian Monte Carlo (HMC) optimized by the No-U-Turn  
416 Sampler (NUTS) (see [25] for details). In particular, we used three chains  
417 with different starting points and ran 3000 iterations for each chain. The  
418 first 1000 iterations were discarded as burn-in, and we retained 6000 samples  
419 in total from the 3 chain (2000 for each). Detailed diagnostics and results  
420 can be found in S1 Text in *Supporting Information*.

#### 421 *Model prediction*

The model prediction for any quantities  $z$  and data  $y$  given parameter set  $\theta$ , we compute

$$p(z|y) = \int p(z|\theta)p(\theta|y)d\theta. \quad (11)$$

Here, quantities  $z$  are viral reproduction number, the maximal epithelium loss and the cumulation of dead cells. The effective reproduction number of viral replication ( $R_t$ ) is given by

$$R_t = \frac{p_I \beta T(t)}{(\delta_I + \kappa_E t^4 / (t^4 + t_E^4) + \kappa_F F(t))(\delta_V + \kappa_A t^4 / (t^4 + t_A^4) + q' M_R(t))}, \quad (12)$$

where  $T(t)$ ,  $F(t)$  and  $M_R(t)$  are the number of susceptible of epithelial cells, interferons and resting macrophages during infection. The killing effect of  $CD8^+$  T cells and the neutralization effect of antibodies are represented by  $\kappa_E t^4 / (t^4 + t_E^4)$  and  $\kappa_A t^4 / (t^4 + t_A^4)$ , respectively. At  $t = 0$ ,  $T(0) = T_0$ ,  $F(0) = 0$  and  $M_R(0) = s / \delta_{MR}$ , and  $R_0$  is called the basic reproduction number of viral infection, which simplifies to

$$R_0 = \frac{p_I \beta T_0}{\delta_I (\delta_V + q' s / \delta_{MR})}, \quad (13)$$

The maximal % of epithelium loss is given by

$$1 - \min(T(t) + R(t)) / T_0 \times 100\%, \quad (14)$$

where  $T(t)$  and  $R(t)$  are the number of susceptible and refractory epithelial cells during infection, and  $T_0$  is the initial number of available susceptible cells. The area under the dead cell curve ( $AUC_D$ ) is given by

$$AUC_D = \int_0^\tau D(t) dt, \quad (15)$$

$\tau$  is a cut-off day for calculation, and we set  $\tau = 10$  to cover viral and macrophage dynamics shown in [18].  $D(t)$  is simulated time series of dead cells. The relative contribution of macrophages on viral clearance is given by

$$q' M_R(t) V(t) / (\delta_V V(t) + q' M_R(t) V(t) + \kappa_A (t^4 / t^4 + t_A^4)), \quad (16)$$

422 where  $M_R(t)$  and  $V(t)$  are the number of resting macrophages and viral loads  
423 during infection. The prediction of tissue damage and the reproduction num-  
424 ber were computed using 6000 posterior samples by solving the ordinary dif-  
425 ferential equations (ODEs) solver `ode15s` in MATLAB R2022a with a relative  
426 tolerance of  $1 \times 10^{-5}$  and an absolute tolerance of  $1 \times 10^{-10}$ . The initial values  
427 were  $(M_R, M_1, M_2, T, L, I, V, F, R, D) = (s / \delta_{MR}, 0, 0, T_0, 0, 0, V_0, 0, 0, 0)$ . All  
428 visualization was performed in R (version 4.0.2), and codes to produce all  
429 figures are available at <https://github.com/keli5734/virulence>.

#### 430 *A simulation and estimation study*

431 A simulation and estimation study is conducted prior to implement the  
432 real dataset. The purpose of the simulation and estimation study is to ex-  
433 plore if extra macrophage data provides more information to better estimate  
434 model parameters and reproduce viral and macrophage dynamics. We use  
435 simulation and mathematical model to show that macrophage data can be

436 used to accurately the recruitment rate of macrophages, inferring the timing  
437 and strength of the increase of macrophage during influenza viral infection.  
438 By contrast, viral load data alone cannot be used to reliably recover the  
439 macrophage dynamics. Hence, the combination of viral load and macrophage  
440 data in model fitting enhances our ability to replicate macrophage dynamics  
441 and allows us to explore detailed macrophage-virus interactions, e.g., the con-  
442 tribution of macrophages (both in timing and strength) on viral clearance.  
443 Detailed study design and outcome can be found in S3 Text in *Supporting*  
444 *Information*.

#### 445 **Supporting Information**

## Enhanced infectivity and attenuation of interferon production are associated with high pathogenicity for influenza viruses


Ke Li, James M McCaw, Pengxing Cao

446

### S1 Text

#### Convergence diagnostics for the MCMC chains

Figures A and B show trace plots for the evolution of estimated parameter vector over the iterations of 3 Markov chains for implementing H1N1 and H5N1 virus, respectively. For each chain, the iteration number is 3000 with the first 1000 samples as burn-in. We observe that all three chains do overlap together, indicating convergence has occurred. Tables A and B show the credible intervals, effective sample size and  $\hat{r}$  of each estimated parameters for HP and LP strains of H1N1 or H5N1 virus, respectively. We find that the effective sample size is sufficient and  $\hat{r}$  is below 1.1 for every parameter, suggesting convergence.



**Figure A** Trace plots of estimated parameters for the fitting H1N1 viral and macrophage data. Three chains were used with 3000 iterations and first 1000 iterations as burn-in (grey area). All parameters are log-transformed. The Parameter vector for HP  $\Phi_{HP} = (s_V, \beta, q_{FI}, q_{FM}, s_M, \kappa_A, q', V_0)$ , and  $\Phi_{LP} = (s_V, \beta, q_{FI}, q_{FM}, \kappa_A, q')$  for LP. We assume  $s_M$  and  $V_0$  are the same for both HP and LP strains.  $\sigma_1, \sigma_2$  are error

structure for the prior distribution of standard deviation the observed log-transformed viral load and macrophage data.




Figure B Trace plots of estimated parameters for the fitting H5N1 viral and macrophage data.

	mean	se_mean	sd	2.5%	25%	50%	75%	97.5%	n_eff	Rhat
log10_theta_HP[1]	0.91	0.01	0.45	-0.02	0.60	0.96	1.24	1.70	1535	1.00
log10_theta_HP[2]	-7.20	0.01	0.23	-7.70	-7.35	-7.15	-7.03	-6.84	1076	1.00
log10_theta_HP[3]	-3.94	0.02	0.68	-5.51	-4.33	-3.78	-3.43	-3.02	1014	1.01
log10_theta_HP[4]	-8.48	0.04	2.15	-13.30	-9.81	-8.19	-6.80	-5.34	3351	1.00
log10_theta_HP[5]	1.33	0.01	0.69	-0.21	0.92	1.38	1.81	2.51	2724	1.00
log10_theta_HP[6]	1.97	0.01	0.37	1.14	1.76	1.99	2.20	2.66	3152	1.00
log10_theta_HP[7]	-7.82	0.04	2.00	-12.43	-9.07	-7.51	-6.21	-5.02	2428	1.00
log10_theta_HP[8]	-0.17	0.02	0.84	-1.78	-0.75	-0.21	0.38	1.53	1486	1.00
log10_theta_LP[1]	2.36	0.01	0.43	1.39	2.16	2.40	2.62	3.06	1499	1.00
log10_theta_LP[2]	-7.89	0.00	0.18	-8.26	-8.01	-7.89	-7.77	-7.55	2026	1.00
log10_theta_LP[3]	-2.21	0.03	0.56	-3.31	-2.37	-2.11	-1.92	-1.60	438	1.00
log10_theta_LP[4]	-8.27	0.04	2.23	-13.26	-9.68	-7.98	-6.50	-4.98	3159	1.00
log10_theta_LP[5]	0.86	0.02	0.69	-0.58	0.44	0.88	1.31	2.18	2055	1.00
log10_theta_LP[6]	-7.92	0.04	2.03	-12.67	-9.08	-7.60	-6.44	-4.85	2883	1.00
sigma[1]	1.24	0.01	0.48	0.58	0.88	1.13	1.51	2.39	1047	1.00
sigma[2]	0.93	0.01	0.27	0.52	0.74	0.89	1.08	1.58	1815	1.00

**Table A Credible intervals, effective sample sizes and  $\hat{r}$  for each estimated parameter of HP and LP strains for H1N1 virus.** The first 1000 iterations are discarded as burn-in, leaving 6000 samples across the three chains.

	mean	se_mean	sd	2.5%	25%	50%	75%	97.5%	n_eff	Rhat
log10_theta_HP[1]	0.87	0.01	0.51	-0.08	0.52	0.89	1.22	1.81	1613	1.00
log10_theta_HP[2]	-7.24	0.01	0.24	-7.72	-7.41	-7.23	-7.07	-6.82	1859	1.00
log10_theta_HP[3]	-4.01	0.02	0.69	-5.52	-4.45	-3.88	-3.49	-2.97	1617	1.00
log10_theta_HP[4]	-8.45	0.04	2.17	-13.37	-9.81	-8.09	-6.78	-5.35	3277	1.00
log10_theta_HP[5]	1.16	0.01	0.70	-0.32	0.71	1.21	1.66	2.39	3527	1.00
log10_theta_HP[6]	1.99	0.02	0.53	0.91	1.72	1.98	2.24	3.18	649	1.00
log10_theta_HP[7]	-7.87	0.04	1.99	-12.57	-9.08	-7.54	-6.36	-5.03	2456	1.00
log10_theta_HP[8]	0.22	0.02	0.91	-1.59	-0.39	0.22	0.82	2.03	2317	1.00
log10_theta_LP[1]	2.16	0.03	0.64	0.66	1.87	2.24	2.54	3.11	616	1.00
log10_theta_LP[2]	-7.87	0.01	0.24	-8.36	-8.03	-7.85	-7.69	-7.44	730	1.00
log10_theta_LP[3]	-2.98	0.06	1.12	-6.47	-3.12	-2.73	-2.43	-1.93	330	1.01
log10_theta_LP[4]	-8.41	0.04	2.10	-13.03	-9.78	-8.11	-6.77	-5.35	3412	1.00
log10_theta_LP[5]	1.06	0.01	0.71	-0.46	0.62	1.10	1.54	2.37	2256	1.00
log10_theta_LP[6]	-8.08	0.04	2.00	-12.61	-9.23	-7.76	-6.61	-5.04	2715	1.00
sigma[1]	1.74	0.02	0.50	0.81	1.40	1.72	2.05	2.80	918	1.00
sigma[2]	0.93	0.02	0.38	0.47	0.67	0.82	1.07	1.96	416	1.01

**Table B Credible intervals, effective sample sizes and  $\hat{r}$  for each estimated parameter of HP and LP strains for H5N1 virus.**

## Enhanced infectivity and attenuation of interferon production are associated with high pathogenicity for influenza viruses

449

Ke Li, James M McCaw, Pengxing Cao

S2 Text

Parameter tables

### Fixed Parameter table (Table S1)

Parameter	Description	Value [refs]	Unit
$\delta_{MR}$	Decay rate of $M_R$ macrophages	1.1e-2 [9]	/day
$k_{-1}$	Conversion rate from $M_1$ to $M_R$	0.3 [2]	/day
$k_{-2}$	Conversion rate from $M_2$ to $M_R$	0.3 [2]	/day
$\delta_{M1}$	Decay rate of $M_1$ macrophages	1.1e-2 [9]	/day
$\delta_{M2}$	Decay rate of $M_2$ macrophages	1.1e-2 [9]	/day
$k_1$	Conversion rate from $M_R$ to $M_1$	0.4 [2]	/day
$k_2$	Conversion rate from $M_R$ to $M_2$	4e-5 [2]	/day
$V_{50}$	Half saturation of viral load to activate $M_1$ macrophages.	1e+7	PFU/ml
$\alpha$	Effectiveness of $M_2$ attenuates $M_R$ to $M_1$	1e-4	/cell
$D_{50}$	Half saturation of dead cells	1e+6	cell
$g_T$	Regrowth rate of epithelium	0.8 [6]	/day
$T_{max}$	The maximal epithelium cells	7e+7 [7]	cell
$\delta_I$	Decay rate of infected cells	2 [1,8,10]	/day
$\delta_V$	Decay rate of virus	5 [1,8,10]	/day
$\kappa_F$	Clearance rate of infected cells by interferons	3 [7]	/(day [ $\mu_F$ ])
$\kappa_E$	Clearance rate of infected cells by CD8+T cells	8 [6]	/day
$\kappa_D$	Clearance rate of dead cells by $M_1$ macrophages	8e-7 [11]	/(day cell)
$\delta_D$	Decay rate of dead cells	2 [11]	/day
$p_I$	Viral production rate	210 [6]	pfu/(ml cell day)
$\delta_F$	Decay rate of interferons	2 [6]	/day

\*[ $\mu_F$ ] is the unit for interferon

$\phi$	Conversion rate from $T$ to $R$	0.33 [6]	/(day [ $\mu_F$ ])
$\xi_R$	Conversion rate from $R$ to $T$	2.6 [6]	/day
$t_E$	Half saturation term of CD8+ T cell response	5	day
$t_A$	Half saturation term of antibody response	5	day
$\ell$	Eclipse phase	4 [5]	/day

### Estimated Parameter table (Table S2)

Parameter	Description	Prior [refs]	Unit
$\log_{10}(s_V)$	Recruitment rate of $M_1$ due to infection	Normal(-1,2) [2,4,5,6,9]	/day
$\log_{10}(\beta)$	Viral infectivity rate	Normal(-6,3) [1,3,5,7,8,10,11]	/(pfu/ml day)
$\log_{10}(q_{FI})$	IFN production rate by infected cells	Normal(-6,3) [7,8]	$[\mu_F]$ /(day cell)
$\log_{10}(q_{FM})$	IFN production rate by $M_1$ macrophages	Normal(-6,3) [12]	$[\mu_F]$ /(day cell)
$\log_{10}(s_M)$	Recruitment rate of macrophages in homeostasis	Normal(2,1) [2,4,5,6,9]	cell/day
$\log_{10}(\kappa_A)$	Neutralization rate of antibodies on viruses	Normal(2,1) [7,8,10]	/day
$\log_{10}(q')$	Engulfment rate of macrophages on viruses	Normal(-6,3)	/(day cell)
$\log_{10}(V_0)$	Viral inoculation size	Normal(1,1) [13]	pfu/ml



## Reference

451

1. Baccam, P., Beauchemin, C., Macken, C.A., Hayden, F.G. and Perelson, A.S., 2006. Kinetics of influenza A virus infection in humans. *Journal of virology*, 80(15), pp.7590-7599.
2. Eftimie, R. and Hamam, H., 2017. Modelling and investigation of the CD4+ T cells–macrophages paradox in melanoma immunotherapies. *Journal of theoretical biology*, 420, pp.82-104.
3. Pawelek, K.A., Huynh, G.T., Quinlivan, M., Cullinane, A., Rong, L. and Perelson, A.S., 2012. Modeling within-host dynamics of influenza virus infection including immune responses. *PLoS computational biology*, 8(6), p.e1002588.
4. Smith, A.M., McCullers, J.A. and Adler, F.R., 2011. Mathematical model of a three-stage innate immune response to a pneumococcal lung infection. *Journal of theoretical biology*, 276(1), pp.106-116.
5. Smith, A.M., Adler, F.R., McAuley, J.L., Gutenkunst, R.N., Ribeiro, R.M., McCullers, J.A. and Perelson, A.S., 2011. Effect of 1918 PB1-F2 expression on influenza A virus infection kinetics. *PLoS computational biology*, 7(2), p.e1001081.
6. Li, X., Jolly, M.K., George, J.T., Pienta, K.J. and Levine, H., 2019. Computational modeling of the crosstalk between macrophage polarization and tumor cell plasticity in the tumor microenvironment. *Frontiers in oncology*, 9, p.10.
7. Cao, P., Wang, Z., Yan, A.W., McVernon, J., Xu, J., Heffernan, J.M., Kedzierska, K. and McCaw, J.M., 2016. On the role of CD8+ T cells in determining recovery time from influenza virus infection. *Frontiers in immunology*, 7, p.611.
8. Yan, A.W., Zaloumis, S.G., Simpson, J.A. and McCaw, J.M., 2019. Sequential infection experiments for quantifying innate and adaptive immunity during influenza infection. *PLoS computational biology*, 15(1), p.e1006568.
9. Wigginton, J.E. and Kirschner, D., 2001. A model to predict cell-mediated immune regulatory mechanisms during human infection with Mycobacterium tuberculosis. *The Journal of Immunology*, 166(3), pp.1951-1967.
10. Miao, H., Hollenbaugh, J.A., Zand, M.S., Holden-Wiltse, J., Mosmann, T.R., Perelson, A.S., Wu, H. and Topham, D.J., 2010. Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. *Journal of virology*, 84(13), pp.6687-6698.
11. Petrie, S.M., Guarnaccia, T., Laurie, K.L., Hurt, A.C., McVernon, J. and McCaw, J.M., 2013. Reducing uncertainty in within-host parameter estimates of influenza infection by measuring both infectious and total viral load. *PLoS One*, 8(5), p.e64098.
12. Jenner, A.L., Aogo, R.A., Alfonso, S., Crowe, V., Deng, X., Smith, A.P., Morel, P.A., Davis, C.L., Smith, A.M. and Craig, M., 2021. COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes. *PLoS pathogens*, 17(7), p.e1009753.

13. Perrone, L.A., Plowden, J.K., García-Sastre, A., Katz, J.M. and Tumpey, T.M., 2008. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. *PLoS pathogens*, 4(8), p.e1000115.

## Enhanced infectivity and attenuation of interferon production are associated with high pathogenicity for influenza viruses

Ke Li, James M McCaw, Pengxing Cao

453

### S3 Text

#### Simulation and estimation study

The purpose of the simulation and estimation study is to explore if extra macrophage data provides more information to better estimate model parameters and reproduce viral and macrophage dynamics. We use simulation and mathematical model to show that macrophage data can be used to accurately the recruitment rate of macrophages, inferring the timing and strength of the increase of macrophage during influenza viral infection. By contrast, viral load data alone cannot be used to reliably recover the macrophage dynamics. Hence, the combination of viral load and macrophage data in model fitting enhances our ability to replicate macrophage dynamics and allows us to explore detailed macrophage-virus interactions, e.g., the contribution of macrophages (both in timing and strength) on viral clearance.


#### Generation of synthetic viral load and macrophage data

We first generate synthetic data for viral loads and macrophages mimicking the experimental procedure. We assume “true” parameter values are known (see Table 1). We do model (details in main text) simulation using the parameter values to get “true” trajectory of viral load and macrophages dynamics across infection period. The “true” parameters are selected such that (1) viral load peaks around day 2 post infection; (2) viral load is below a detection limit around day 7 post infection; (3) the adaptive immune responses (i.e., antibody and CD8+T cells) only activate after day 5 post infection; (4) viral infection can be suppressed timely when both arms of adaptive immune responses (i.e., antibody and CD8+T cells) are presented; (5) virus can be cleared but clearance delays when there is only an antibody response, and (6) a chronic infection occurs when an antibody response is suppressed (Figure 1C). A detailed model dynamics see Figure 1.

Further, we get observation viral load and macrophage data from the “true” trajectory by adding lognormal noise and imposing a detection limit. Mathematically, the measured viral load  $V_{n,\tau}$  and macrophage  $M_{n,\tau}$  for each mouse  $n = 1, 2, \dots, N$  and measuring time point  $\tau = 1, 2, \dots, T$  are given by

$$V_{n,\tau} = \begin{cases} V_{true}(\tau, \Phi)10^{e_{n,\tau}}, & \text{if } V_{true}(\tau, \Phi)10^{e_{n,\tau}} \geq \Theta \\ 0, & \text{otherwise} \end{cases} \quad \text{and} \quad M_{n,\tau} = M_{true}(\tau, \Phi)10^{e_{n,\tau}}$$

$\Phi$  is a vector of “true” parameter values.  $e_{n,\tau}$  is the measurement error, which follows  $N(0, \sigma)$ , and  $\sigma = 1$  for viral load data and  $\sigma = 0.1$  for macrophage data.  $\Theta$  is detection limit.  $V_{true}(\tau, \Phi)$  is the “true” viral load value at each measuring time  $\tau$ , and  $M_{true}(\tau, \Phi)$  is the “true” macrophage value at each measuring time  $\tau$ . Here, we select  $N = 5$  to indicate at each measuring time 5 data points are measured, and we set  $\tau = 7$ . As shown in Figures 1A and B, the open circles indicate measured data points at each measuring time for viral load and macrophages, respectively. The red cycles indicate the mean value of the 5 data point at each time, and we only use the red data points of viral load and macrophage populations for the model estimation.



**Figure 1** The synthetic data for (A) viral load, (B) macrophages. (C) “true” parameter values are selected such that viral loads have different behaviours when different arms of adaptive immune responses are suppressed.

**Table 1:** “true” parameter values to generate true viral load and macrophages trajectories

Parameter	Description	Value	Unit
$\delta_{MR}$	Decay rate of $M_R$ macrophages	3.3e+3	/day
$k_{-1}$	Conversion rate from $M_1$ to $M_R$	0.3	/day
$k_{-2}$	Conversion rate from $M_2$ to $M_R$	0.3	/day
$\delta_{M1}$	Decay rate of $M_1$ macrophages	1.1e-2	/day
$\delta_{M2}$	Decay rate of $M_2$ macrophages	1.1e-2	/day
$k_1$	Conversion rate from $M_R$ to $M_1$	0.4	/day
$k_2$	Conversion rate from $M_R$ to $M_2$	4e-6	/day
$V_{50}$	Half saturation of viral load to activate $M_1$ macrophages.	1e+7	PFU/ml
$\alpha$	Effectiveness of $M_2$ attenuates $M_R$ to $M_1$	1e-4	/cell
$D_{50}$	Half saturation of dead cells	1e+6	cell
$g_T$	Regrowth rate of epithelium	0.8	/day
$T_{max}$	The maximal epithelium cells	7e+7	cell
$\delta_I$	Decay rate of infected cells	2	/day
$\delta_V$	Decay rate of virus	20	/day

$\kappa_F$	Clearance rate of infected cells by interferons	3	/(day [ $\mu_F$ ]) * $[\mu_F]$ is the unit for interferon
$\kappa_E$	Clearance rate of infected cells by CD8+T cells	8	/day
<sup>455</sup> $\kappa_D$	Clearance rate of dead cells by $M_1$ macrophages	8e-7	/(day cell)
$\delta_D$	Decay rate of dead cells	2	/day
$p_I$	Viral production rate	210	pfu/(ml cell day)
$\delta_F$	Decay rate of interferons	2	/day
$\phi$	Conversion rate from $T$ to $R$	0.33	/(day [ $\mu_F$ ])
$\xi_R$	Conversion rate from $R$ to $T$	2.6	/day
$\ell$	Eclipse phase	4	/day
$t_E$	Half saturation time of CD8+ T cell response	5	day
$t_A$	Half saturation time of antibody response	5	day


### Bayesian statistical inference

Two scenarios were considered, one of which is using viral load data only, and the other is using both viral load and macrophage data. We applied a Bayesian inference method to fit the dynamic model (detailed in the main text) to the log-transformed kinetic data. In detail, we use the model to estimate 8 parameters, and the parameter space is denoted as  $\Phi = (s_V, \beta, q_{FI}, q_{FM}, s_M, \kappa_A, q', V_0)$ . Upon model calibration, we fixed all other parameters their “true” values as shown in Table 1.

The prior distribution for the estimated model parameters is given in Table S2 in Supplementary Materials 2. The distribution of the observed log-transformed viral load and/or macrophage data is assumed to be a normal distribution with a mean value given by the model simulation results and standard deviation (SD) parameter with prior distribution of a normal distribution with a mean of 0 and a SD of 1.


Model fitting was performed in R (version 4.0.2) and Stan (Rstan 2.21.0). Samples were drawn from the joint posterior distribution of the model parameters using Hamiltonian Monte Carlo (HMC) optimized by the No-U-Turn Sampler (NUTS) (details see Chatzilena et al. (2019)). In particular, we used 4 chains with different starting points and ran 8000 iterations (first 3000 samples are burn-in) for each chain when only viral load data is used. We also tried to run 2000, 4000 and 6000 iterations, respectively and effective sample size is small. When viral load data and macrophages are both used, we ran 4 chains with 2000 iterations (first 1000 samples are burn-in) for each chain.

## Predictive check




**Figure 2 Results of model fitting for virological and macrophage data.** Data are presented by solid circles. (A) shows a 95% prediction interval (shaded area) of reproduced viral dynamics by using viral load data only (red) or both viral load and macrophage data (green). (B) shows a 95% prediction interval (shaded area) of reproduced macrophage kinetics by using viral load data only (red) or both viral load and macrophage data (green).

## Posterior comparison




**Figure 3 Posterior distributions of estimated parameters.** Purple bars show posterior density of parameters when only viral load data is used. Green bars show posterior density of parameters when both viral load and macrophage data are used. Red lines indicate the “true” parameter values.

## Diagnostics



**Figure 4 Trace plots of estimated parameters using only viral load data.** Four chains were used with 8000 iterations and first 3000 iterations as burn-in (grey area). All parameters are log-transformed. The parameter vector is  $\Phi = (s_V, \beta, q_{FI}, q_{FM}, s_M, \kappa_A, q', V_0)$ .



**Figure 5** Trace plots of estimated parameters using both viral load and macrophage data. Four chains were used with 2000 iterations and first 1000 iterations as burn-in (grey area). All parameters are log-transformed. The parameter vector is  $\Phi = (s_V, \beta, q_{FI}, q_{FM}, s_M, \kappa_A, q', V_0)$ .

## Reference

1. Chatzilena, A., van Leeuwen, E., Ratmann, O., Baguelin, M. and Demiris, N., 2019. Contemporary statistical inference for infectious disease models using Stan. *Epidemics*, 29, p.100367.




## Enhanced infectivity and attenuation of interferon production are associated with high pathogenicity for influenza viruses


Ke Li, James M McCaw, Pengxing Cao

459


### Supplementary Figures




**Sfig 1** Posterior distributions of parameters for H1N1 virus. Green bars indicate the posterior density for HP strain and purple bars indicate the posterior density for LP strain. Green and purple dashed lines indicate the median estimation of each parameter for HP and LP, respectively. Prior distribution for each parameter is given by black curve.




**Sfig 2** Posterior distributions of parameters for H5N1 virus. Green bars indicate the posterior density for HP strain and purple bars indicate the posterior density for LP strain. Green and purple dashed lines indicate the median estimation of each parameter for HP and LP, respectively. Prior distribution for each parameter is given by black curve.




**SFig 3 Prediction of tissue damage for H5N1 viruses.** The violin plots (coloured) and boxplots (white) give the density and the median and extrema of predicted quantity. (A) model prediction of the maximal epithelium loss for the HP (yellow) and green (LP) strain. (B) model prediction of the cumulative level of dead cells during the infection for both strains. \*\*\*  $p < 0.001$ . Calculation formula see Eq. (13) in the main text. All estimations are computed using 6000 posterior samples from model fitting.




**SFig 4** The proportional of epithelium loss during HP and LP H1N1 viral infections. The calculation of epithelium loss is given in the main text. All estimations are computed using 6000 posterior samples from model fitting.



**SFig 5 Comparison of estimated model parameters between HP and LP strains of the H5N1 viruses.** Histograms show the frequency of the quotient of estimated HP parameters over paired LP model parameters and are normalised to [0,1]. The cumulative density functions (CDF) are given by the solid lines. All quotients are log<sub>10</sub>-scaled, such that quotient > 0 suggests greater values of the HP parameters. Dark green indicates quotients > 0, and light green indicates quotients < 0. First row (from left to right) the quotients of viral infectivity, interferon production rate from infected cells and activated macrophages, respectively. Second row (from left to right) the quotients of infection-induced macrophage recruitment rate, macrophage-mediated virus clearance rate and antibody neutralisation rate, respectively.



**SFig 6** The relative contribution of macrophages on viral clearance in the HP and LP strains of the H5N1 viruses. The relative contribution is given by  $q' M_R(t) V(t) / (\delta_V V(t) + q' M_R(t) V(t) + \kappa_A (t^4 / t^4 + t_{50}^4))$ , where  $M_R(t)$  and  $V(t)$  are the number of resting macrophages and viral loads during infection. The prediction interval (PI) is calculated based upon the 6000 posterior samples from model fitting. The median trajectory is indicated by black curve.



**SFig 7 Detailed macrophage dynamics during HP and LP H1N1 viral infections.** Y-axis gives the proportion of each type of macrophages to overall number of macrophages at each measuring time. Grey lines are macrophage trajectories calculated based upon 6000 posterior samples from model fitting, and the median trajectory is indicated by red curve.

466 **Acknowledgements**

467 Ke Li is supported by a Melbourne Research Scholarship. This work  
468 was supported by an Australian Research Council (ARC) Discovery Project  
469 (DP170103076 and DP210101920) and a National Health and Medical Re-  
470 search Council (NHMRC) funded Centre for Research Excellence in Infec-  
471 tious Diseases Modelling to Inform Public Health Policy (1078068).

472 **Author contributions**

473 **Ke Li:** Conceptualization, Methodology, Software, Formal analysis, Writing-  
474 Original Draft. **James M. McCaw** Methodology, Formal analysis, Writing-  
475 Review and Editing, Supervision. **Pengxing Cao:** Methodology, Formal  
476 analysis, Writing- Review and Editing, Supervision



477 **References**

- 478 [1] Moghadami M. A narrative review of influenza: a seasonal and pandemic  
479 disease. *Iranian journal of medical sciences*. 2017;42(1):2.
- 480 [2] Winternitz MC, McNamara FP, Wason IM. *The pathology of influenza*.  
481 4. Yale University Press; 1920.
- 482 [3] Beigel J. The Writing Committee of the World Health Organization  
483 (WHO) Consultation on Human Influenza A/H5. Avian influenza A  
484 (H5N1) infection in humans. *N Engl J Med*. 2005;353:1374-85.
- 485 [4] Taubenberger JK, Morens DM. The pathology of influenza virus infec-  
486 tions. *Annual review of pathology*. 2008;3:499.
- 487 [5] Szretter KJ, Gangappa S, Lu X, Smith C, Shieh WJ, Zaki SR, et al. Role  
488 of host cytokine responses in the pathogenesis of avian H5N1 influenza  
489 viruses in mice. *Journal of virology*. 2007;81(6):2736-44.
- 490 [6] Kuiken T, Rimmelzwaan G, Van Amerongen G, Osterhaus A. Pathology  
491 of human influenza A (H5N1) virus infection in cynomolgus macaques  
492 (*Macaca fascicularis*). *Veterinary pathology*. 2003;40(3):304-10.
- 493 [7] Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, et al.  
494 Aberrant innate immune response in lethal infection of macaques with  
495 the 1918 influenza virus. *Nature*. 2007;445(7125):319-23.
- 496 [8] Kash JC, Tumpey TM, Proll SC, Carter V, Perwitasari O, Thomas  
497 MJ, et al. Genomic analysis of increased host immune and cell death  
498 responses induced by 1918 influenza virus. *Nature*. 2006;443(7111):578-  
499 81.
- 500 [9] Heui Seo S, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses es-  
501 cape host anti-viral cytokine responses. *Nature medicine*. 2002;8(9):950-  
502 4.
- 503 [10] Smallman-Raynor M, Cliff AD. Avian influenza A (H5N1) age distribu-  
504 tion in humans. *Emerging infectious diseases*. 2007;13(3):510.
- 505 [11] Fukuyama S, Kawaoka Y. The pathogenesis of influenza virus infec-  
506 tions: the contributions of virus and host factors. *Current opinion in*  
507 *immunology*. 2011;23(4):481-6.

- 508 [12] Cheung C, Poon L, Lau A, Luk W, Lau Y, Shortridge K, et al. Induction  
509 of proinflammatory cytokines in human macrophages by influenza A  
510 (H5N1) viruses: a mechanism for the unusual severity of human disease?  
511 *The Lancet*. 2002;360(9348):1831-7.
- 512 [13] De Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TNB,  
513 et al. Fatal outcome of human influenza A (H5N1) is associated with high  
514 viral load and hypercytokinemia. *Nature medicine*. 2006;12(10):1203-7.
- 515 [14] La Gruta NL, Kedzierska K, Stambas J, Doherty PC. A question of  
516 self-preservation: immunopathology in influenza virus infection. *Im-*  
517 *munology and cell biology*. 2007;85(2):85-92.
- 518 [15] Yu WC, Chan RW, Wang J, Travanty EA, Nicholls JM, Peiris JM, et al.  
519 Viral replication and innate host responses in primary human alveolar  
520 epithelial cells and alveolar macrophages infected with influenza H5N1  
521 and H1N1 viruses. *Journal of virology*. 2011;85(14):6844-55.
- 522 [16] van Riel D, Leijten LM, van der Eerden M, Hoogsteden HC, Boven LA,  
523 Lambrecht BN, et al. Highly pathogenic avian influenza virus H5N1  
524 infects alveolar macrophages without virus production or excessive TNF-  
525 alpha induction. *PLoS pathogens*. 2011;7(6):e1002099.
- 526 [17] Cline TD, Beck D, Bianchini E. Influenza virus replication in  
527 macrophages: balancing protection and pathogenesis. *The Journal of*  
528 *general virology*. 2017;98(10):2401.
- 529 [18] Perrone LA, Plowden JK, Garcia-Sastre A, Katz JM, Tumpey TM.  
530 H5N1 and 1918 pandemic influenza virus infection results in early and  
531 excessive infiltration of macrophages and neutrophils in the lungs of  
532 mice. *PLoS pathogens*. 2008;4(8):e1000115.
- 533 [19] Handel A, Liao LE, Beauchemin CA. Progress and trends in mathe-  
534 matical modelling of influenza A virus infections. *Current Opinion in*  
535 *Systems Biology*. 2018;12:30-6.
- 536 [20] Pawelek KA, Dor Jr D, Salmeron C, Handel A. Within-host mod-  
537 els of high and low pathogenic influenza virus infections: The role of  
538 macrophages. *PloS one*. 2016;11(2):e0150568.
- 539 [21] Ackerman EE, Weaver JJ, Shoemaker JE. Mathematical Modeling Finds  
540 Disparate Interferon Production Rates Drive Strain-Specific Immunody-  
541 namics during Deadly Influenza Infection. *Viruses*. 2022;14(5):906.

- 542 [22] Shoemaker JE, Fukuyama S, Einfeld AJ, Zhao D, Kawakami E, Sakabe  
543 S, et al. An ultrasensitive mechanism regulates influenza virus-induced  
544 inflammation. *PLoS pathogens*. 2015;11(6):e1004856.
- 545 [23] Cao P, Yan AW, Heffernan JM, Petrie S, Moss RG, Carolan LA, et al.  
546 Innate immunity and the inter-exposure interval determine the dynamics  
547 of secondary influenza virus infection and explain observed viral hierar-  
548 chies. *PLoS computational biology*. 2015;11(8):e1004334.
- 549 [24] Elster C, Wübbeler G. Bayesian regression versus application of least  
550 squares—an example. *Metrologia*. 2015;53(1):S10.
- 551 [25] Chatzilena A, van Leeuwen E, Ratmann O, Baguelin M, Demiris N.  
552 Contemporary statistical inference for infectious disease models using  
553 Stan. *Epidemics*. 2019;29:100367.
- 554 [26] Rouse BT, Sehrawat S. Immunity and immunopathology to  
555 viruses: what decides the outcome? *Nature Reviews Immunology*.  
556 2010;10(7):514-26.
- 557 [27] Sumbria D, Berber E, Rouse BT. Factors affecting the tissue damaging  
558 consequences of viral infections. *Frontiers in microbiology*. 2019:2314.
- 559 [28] Tumpey TM, Garcia-Sastre A, Taubenberger JK, Palese P, Swayne DE,  
560 Pantin-Jackwood MJ, et al. Pathogenicity of influenza viruses with genes  
561 from the 1918 pandemic virus: functional roles of alveolar macrophages  
562 and neutrophils in limiting virus replication and mortality in mice. *Jour-  
563 nal of virology*. 2005;79(23):14933-44.
- 564 [29] Taubenberger JK, Kash JC. Insights on influenza pathogenesis from the  
565 grave. *Virus research*. 2011;162(1-2):2-7.
- 566 [30] Tumpey TM, Lu X, Morken T, Zaki SR, Katz JM. Depletion of lym-  
567 phocytes and diminished cytokine production in mice infected with a  
568 highly virulent influenza A (H5N1) virus isolated from humans. *Journal  
569 of virology*. 2000;74(13):6105-16.
- 570 [31] Maines TR, Szretter KJ, Perrone L, Belser JA, Bright RA, Zeng H, et al.  
571 Pathogenesis of emerging avian influenza viruses in mammals and the  
572 host innate immune response. *Immunological reviews*. 2008;225(1):68-  
573 84.
- 574 [32] Szretter KJ, Gangappa S, Belser JA, Zeng H, Chen H, Matsuoka Y,  
575 et al. Early control of H5N1 influenza virus replication by the type I  
576 interferon response in mice. *Journal of virology*. 2009;83(11):5825-34.

- 577 [33] of the World Health Organization (WHO) Consultation on Human In-  
578 fluenza A/H5 WC. Avian influenza A (H5N1) infection in humans. New  
579 England Journal of Medicine. 2005;353(13):1374-85.
- 580 [34] Li W, Wang G, Zhang H, Xin G, Zhang D, Zeng J, et al. Effects of NS1  
581 variants of H5N1 influenza virus on interferon induction, TNF $\alpha$  response  
582 and p53 activity. Cellular & molecular immunology. 2010;7(3):235-42.
- 583 [35] Mok BWY, Liu H, Chen P, Liu S, Lau SY, Huang X, et al. The role  
584 of nuclear NS1 protein in highly pathogenic H5N1 influenza viruses.  
585 Microbes and infection. 2017;19(12):587-96.
- 586 [36] Cao P, Wang Z, Yan AW, McVernon J, Xu J, Heffernan JM, et al. On  
587 the role of CD8+ T cells in determining recovery time from influenza  
588 virus infection. Frontiers in immunology. 2016;7:611.
- 589 [37] Smith AM, Adler FR, McAuley JL, Gutenkunst RN, Ribeiro RM, Mc-  
590 Cullers JA, et al. Effect of 1918 PB1-F2 expression on influenza A virus  
591 infection kinetics. PLoS computational biology. 2011;7(2):e1001081.
- 592 [38] LeCOUNT ER. The pathologic anatomy of influenzal bronchopneumo-  
593 nia. Journal of the American Medical Association. 1919;72(9):650-2.
- 594 [39] Katz JM, Lu X, Tumpey TM, Smith CB, Shaw MW, Subbarao K.  
595 Molecular correlates of influenza A H5N1 virus pathogenesis in mice.  
596 Journal of Virology. 2000;74(22):10807-10.
- 597 [40] Katz J, Lu X, Frace A, Morken T, Zaki S, Tumpey T. Pathogenesis of  
598 and immunity to avian influenza A H5 viruses. Biomedicine & Pharma-  
599 cotherapy. 2000;54(4):178-87.
- 600 [41] Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, Greer PW,  
601 et al. Avian influenza (H5N1) viruses isolated from humans in Asia  
602 in 2004 exhibit increased virulence in mammals. Journal of virology.  
603 2005;79(18):11788-800.
- 604 [42] Cao P, McCaw JM. The mechanisms for within-host influenza virus con-  
605 trol affect model-based assessment and prediction of antiviral treatment.  
606 Viruses. 2017;9(8):197.
- 607 [43] Friesenhagen J, Boergeling Y, Hrinčius E, Ludwig S, Roth J, Viemann  
608 D. Highly pathogenic avian influenza viruses inhibit effective immune  
609 responses of human blood-derived macrophages. Journal of leukocyte  
610 biology. 2012;92(1):11-20.

- 611 [44] Wong CO, Gregory S, Hu H, Chao Y, Sepúlveda VE, He Y, et al. Lyso-  
612 somal degradation is required for sustained phagocytosis of bacteria by  
613 macrophages. *Cell host & microbe*. 2017;21(6):719-30.
- 614 [45] Meischel T, Villalon-Letelier F, Saunders PM, Reading PC, Londrigan  
615 SL. Influenza A virus interactions with macrophages: Lessons from  
616 epithelial cells. *Cellular microbiology*. 2020;22(5):e13170.
- 617 [46] Yan AW, Cao P, Heffernan JM, McVernon J, Quinn KM, La Gruta NL,  
618 et al. Modelling cross-reactivity and memory in the cellular adaptive im-  
619 mune response to influenza infection in the host. *Journal of Theoretical*  
620 *Biology*. 2017;413:34-49.
- 621 [47] Nicol MQ, Dutia BM. The role of macrophages in influenza A virus  
622 infection. *Future Virology*. 2014;9(9):847-62.
- 623 [48] Mills CD. Anatomy of a discovery: M1 and M2 macrophages. *Frontiers*  
624 *in immunology*. 2015;6:212.
- 625 [49] Atri C, Guerfali FZ, Laouini D. Role of human macrophage polariza-  
626 tion in inflammation during infectious diseases. *International journal of*  
627 *molecular sciences*. 2018;19(6):1801.
- 628 [50] Miao H, Hollenbaugh JA, Zand MS, Holden-Wiltse J, Mosmann TR,  
629 Perelson AS, et al. Quantifying the early immune response and adap-  
630 tive immune response kinetics in mice infected with influenza A virus.  
631 *Journal of virology*. 2010;84(13):6687-98.